Cancer immunotherapy comes of age and looks for maturity.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32620755.
- Also identified by DOI 10.1038/s41467-020-17140-5 and PMC identifier 7335079.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.
Medical subject headings
- Antibodies, Monoclonal
- Gene Editing
- Immunotherapy
- Neoplasms
- Oncolytic Virotherapy
- Protein Engineering